ハンチントン病の疫学的予測

GlobalDataが発行した調査報告書(GDHCER108-15)
◆英語タイトル:EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024
◆商品コード:GDHCER108-15
◆発行会社(リサーチ会社):GlobalData
◆発行日:2015年12月9日
◆ページ数:49
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥451,435見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,990 ⇒換算¥902,870見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD11,985 ⇒換算¥1,354,305見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、ハンチントン病の疫学的市場予測について調査・分析し、以下の構成でお届けいたします。

・イントロダクション
・ハンチントン病の概要
・リスク要因及び併存症
・主要地域の動向
・疫学的予測方法
・ハンチントン病の疫学的予測結果(有病率など)
・考察(結論、分析の限界・強み)
【レポートの概要】

EpiCast Report: Huntington’s Disease – Epidemiology Forecast to 2024

Summary

Huntington’s disease (HD) is a rare, inherited, genetic disorder that causes progressive degeneration of the nerve cells of the brain especially the caudate, the putamen, and the cerebral cortex. As the brain cells die, a person with HD is unable to control movements, recall events, make decisions, and control emotions, and the disorder leads to incapacitation, cognitive and psychiatric disorders, and eventually death. The signs and symptoms of HD mostly appear between the ages 30-40 years, although the onset of disease may occur earlier or later in life. Therefore the disease is mostly of adult onset. The average lifespan of a person after being diagnosed with adult-onset HD is about 15-20 years. When the onset of the disease begins earlier than the age 20 years, the condition is called juvenile HD. Juvenile HD presents somewhat different symptoms and has a faster disease progression.

GlobalData epidemiologists forecast an increase in the diagnosed prevalence of HD over the ten-year forecast period. The number of diagnosed prevalent cases of HD in the 7MM will increase from 57,314 cases in 2014 to 60,743 cases in 2024, with an AGR of 0.60% during the forecast period. For juvenile HD, GlobalData epidemiologists forecast an increase from 1,000 diagnosed prevalent cases in 2014 to 1,013 diagnosed prevalent cases in 2024, in the 7MM, with an AGR of 0.13%.

GlobalData epidemiologists used the available data on HD to the best extent possible to provide the most insightful epidemiological forecast for the diagnosed prevalent cases of HD, diagnosed prevalent cases of juvenile HD, diagnosed prevalent cases of HD by age at onset, and diagnosed prevalent cases of adults with juvenile-onset HD that progressed to adulthood in the 7MM. All sources for the 7MM assessed HD by diagnostic testing, including genetic tests. Additionally, the forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the projected diagnosed prevalent cases of HD across the markets.

Scope

- The Huntington’s Disease EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for Huntington’s disease (HD) in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of HD and juvenile HD, diagnosed prevalent cases of Huntington’s disease by age at onset, and diagnosed prevalent cases of adults with juvenile onset HD that progressed to adulthood, segmented by age and sex.
- The HD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Huntington’s Disease EpiCast report will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global HD market.
- Quantify patient populations in the global HD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for HD therapeutics in each of the markets covered.

【レポートの目次】

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Complications 10
3.3 Global Trends 11
3.3.1 Diagnosed Prevalence of Huntington’s Disease – 7MM 11
3.4 Forecast Methodology 13
3.4.1 Sources Used 16
3.4.2 Sources Not Used 19
3.4.3 Forecast Assumptions and Methods 19
3.5 Epidemiological Forecast of Huntington’s Disease (2014-2024) 22
3.5.1 Diagnosed Prevalent Cases 22
3.5.2 Diagnosed Prevalent Cases of Huntington’s Disease by Age at Onset 35
3.5.3 Diagnosed Prevalent Cases of Adults with Juvenile Onset Huntington’s Disease that Progressed to Adulthood, Ages ≥20 Years 36
3.6 Discussion 38
3.6.1 Epidemiological Forecast Insight 38
3.6.2 Limitations of the Analysis 39
3.6.3 Strengths of the Analysis 39
4 Appendix 41
4.1 Bibliography 41
4.2 About the Authors 44
4.2.1 Epidemiologists 44
4.2.2 Reviewers 44
4.2.3 Global Director of Therapy Analysis and Epidemiology 45
4.2.4 Global Head of Healthcare 46
4.3 About GlobalData 47
4.4 About EpiCast 47
4.5 Disclaimer 48

1.1 List of Tables
Table 1: Risk Factors and Complications for Huntington’s Disease 10
Table 2: 7MM Estimates for the Diagnosed Prevalence of Huntington’s Disease 13
Table 3: 7MM, Sources of Epidemiological Data Used for the Forecast of Huntington’s Disease Diagnosed Prevalent Cases 14
Table 4: 7MM, Sources of Epidemiological Data Used for the Forecast of Juvenile Huntington’s Disease Diagnosed Prevalent Cases 15
Table 5: 7MM, Sources of Epidemiological Data Used for the Forecast of Huntington’s Disease Diagnosed Prevalent Cases by Age at Onset 16
Table 6: 7MM, Diagnosed Prevalent Cases of Huntington’s Disease, All Ages, Both Sexes, N, 2014-2024 23
Table 7: 7MM, Diagnosed Prevalent Cases of Huntington’s Disease by Age Group, Both Sexes, N (%), 2014 25
Table 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of Huntington’s Disease, All Ages, N (%), 2014 27
Table 9: 7MM, Diagnosed Prevalent Cases of Juvenile Huntington’s Disease, Age <20 Years, Both Sexes, N, 2014-2024 30
Table 10: 7MM, Age-Specific Diagnosed Prevalent Cases of Juvenile Huntington’s Disease, Both Sexes, N (%), 2014 32
Table 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of Juvenile Huntington’s Disease, Age <20 Years, N (%), 2014 34
Table 12: 7MM, Diagnosed Prevalent Cases of Adults with Juvenile-Onset Huntington’s Disease that Progressed to Adulthood, Age ≥20 Years, Both Sexes, N, 2014-2024 37

1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of Huntington’s Disease, All Ages, Both Sexes, N, 2014-2024 23
Figure 2: 7MM, Diagnosed Prevalent Cases of Huntington’s Disease by Age Group, Both Sexes, N, 2014 26
Figure 3: 7MM, Diagnosed Prevalent Cases of Huntington's Disease, by Sex, All Ages, N, 2014 28
Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of Huntington’s Disease (%) by Sex, All Ages, 2014 29
Figure 5: 7MM, Diagnosed Prevalent Cases of Juvenile Huntington’s Disease, Age <20 Years, Both Sexes, N, 2014-2024 31
Figure 6: 7MM, Diagnosed Prevalent Cases of Juvenile Huntington’s Disease by Age Group, Both Sexes, N 33
Figure 7: 7MM, Diagnosed Prevalent Cases of Juvenile Huntington's Disease by Sex, Age <20 Years, N, 2014 35
Figure 8: 7MM, Diagnosed Prevalent Cases of Huntington's Disease by Age at Onset, Both Sexes, N, 2014 36
Figure 9: 7MM, Diagnosed Prevalent Cases of Adults with Juvenile-Onset Huntington's Disease that Progressed to Adulthood, Age ≥20 Years, Both Sexes, N, 2014 37

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ハンチントン病の疫学的予測(EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆